Fibrodysplasia ossificans progressiva (FOP) is a rare hereditary disorder. This disorder causes heterotopic ossification, abnormal development of bone in areas such as skeletal muscles tendons, and ligaments. The body's soft connective tissues and skeletal muscles are transformed into bone, which leads to locking of joints in place and makes the movement difficult or impossible. Fibrodysplasia ossificans progressiva cause malformations such as shortened great toe with a malformed distal first metatarsal, abnormally short fingers and toes (microdactyly), inward turning of the great toe toward the other toes (hallux valgus), and/or permanent fixation of the fifth finger in a bent position (clinodactyly).

Currently, there is no definitive treatment available for fibrodysplasia ossificans progressiva (FOP). However, the disorder can be managed by drugs such corticosteroids which help to reduce the tissue swelling and intense inflammation observed in early stages of fibrodysplasia ossificans progressive (FOP). The unavailability of definitive treatment has encouraged the market players to increase research and development for fibrodysplasia ossificans progressiva, which is likely to drive the market growth during the forecast period.   

Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market – Dynamics

Key players operating in market are increasing their research and development activities for the treatment for fibrodysplasia ossificans progressiva (FOP) which is expected to drive the growth of the global fibrodysplasia ossificans progressiva (FOP) treatment market during the forecast period. For instance, on November 2019, BioCryst Pharmaceuticals, Inc., a pharmaceutical company, initiated phase 1 clinical trial of BCX9250 which is an oral activin receptor-like kinase-2 (ALK-2) inhibitor, developed for the treatment of fibrodysplasia ossificans progressiva (FOP).

Moreover, market players are focusing on various inorganic strategies such as partnerships and agreement to develop the treatment for fibrodysplasia ossificans progressiva (FOP) which is expected to propel the marker growth during the forecast period. For instance, on October 2019, Clementia Pharmaceuticals, a subsidiary of Ipsen, and Blueprint Medicines Corporation entered an exclusive license agreement to commercialize and develop of BLU-782, a highly selective investigational ALK2 inhibitor, indicated for the treatment of fibrodysplasia ossificans progressiva (FOP).

Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market - Regional Insights

Regional segmentation of the global fibrodysplasia ossificans progressiva (FOP) treatment market by Coherent Market Insights includes North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America holds a dominant position in the global fibrodysplasia ossificans progressiva (FOP) treatment market owing to the increasing research and development activities. For instance, on January 2020, Regeneron Pharmaceuticals, Inc., an American pharmaceutical company, released the results from a Phase 2, double-blind placebo-controlled trial, LUMINA-1, the trial was initiated to evaluate garetosmab (REGN2477) for the treatment of fibrodysplasia ossificans progressiva.

Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market - Competitive Landscape

Key players operating in the global fibrodysplasia ossificans progressiva (FOP) treatment   market are Pfizer Inc., AstraZeneca, Limited, Regeneron Pharmaceuticals, Inc, Clementia Pharmaceuticals, Oncodesign, Daiichi Sankyo Company, Novartis AG, Blueprint Medicines Corporation, La Jolla Pharmaceutical Company, Biocryst Pharmaceuticals, Inc., and Nobelpharma Co., Ltd.

Moreover, acquisitions and mergers by market players to expand their product portfolios are likely to propel the market growth during the forecast period. For instance, in April 2019, Ipsen completed the acquisition of Clementia Pharmaceuticals. Through this acquisition Ipsen will be strengthening its portfolio of products for treating rare disorders such as fibrodysplasia ossificans progressiva.

Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market - Market Taxonomy

On the basis of drug type, the global Fibrodysplasia Ossificans Progressiva (FOP) Treatment market is segmented into:

  • Corticosteroids
  • NSAIDs
  • Bisphosphonates
  • Others

On the basis of route of administration, the global fibrodysplasia ossificans progressiva (FOP) treatment market is segmented into:

  • Oral
  • Topical
  • Parenteral

On the basis of distribution channel, the global fibrodysplasia ossificans progressiva (FOP) treatment market is segmented into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

On the basis of region, the global fibrodysplasia ossificans progressiva (FOP) treatment market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
N/A
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner